U T Khader bats for law amendment to ban bars in residential areas

Mangaluru, Jul 23: Dakshina Kannada recorded seven more deaths related to covid-19 even as the district saw a spike of 218 new coronavirus positive cases in past 24 hours. With this the total number of covid related deaths in the district mounted to 99. 

Among the seven fatalities, the first one is a 36-year-old man hailing from Davanagere. He was admitted to a private hospital on July 16, and breathed his last yesterday.He was suffering from sepsis septic shock, acute liver injury, and acute kidney injury, acute chronic pancreatitis, ARDS, and spontaneous bacterial peritonitis. 

The second victim is a 69-year-old man from Bhatkal, who was admitted to a private hospital on July 7, and passed away July 22. He suffered from heart disease, cancer, renal failure and pulmonary thromboembolism. 

The third one is a 52-year-old man from Palakkad, Kerala. He was admitted to a Wenlock hospital on July 19, and passed away on July 22. He suffered from diabetes, ARDS and respiratory issues. 

The fourth one is an 83-year-old man from Mangaluru. He was admitted to a Wenlock hospital on June 13, and passed away on July 22. He suffered from blood pressure, heart disease and pneumonia. 

The fifth one is a 73-year-old man from Mangaluru, who was admitted to a private hospital on July 21, and passed away on July 22. He was suffering from diabetes mellitus, hypertension, old cerebrovascular accident, hyponatraemia and acute on chronic kidney disease. 

The sixth one a 58-year-old woman from Mangaluru. She was admitted to a private hospital on July 11 and passed away on July 22. She was suffering from type 2 diabetes mellitus and hypertension. 

The seventh is a 52-year-old male from Bantwal. He was admitted to private hospital on July 21 and passed away on July 22. He was suffering from heart disease.

As per the district health bulletin, a total of 31,068 samples have been tested so far. 26,854 have turned out negative, and 4,214 are positive till date. Out of these, 2,253 cases are currently active. 1,862 persons have recovered and been discharged. Among the deceased, 12 are from other districts.

As many as 118 patients were discharged on Thursday from Wenlock as well as private hospitals. Of the 218 who tested positive on Thursday, 36 are primary contacts, 110 have ILI symptoms, 16 have SARI symptoms, and contacts of 57 are being traced.

Bengaluru, Apr 8: The Karnataka government is in favour of lifting the coronavirus lockdown in districts which remained free of the virus infection, subject to approval from the Centre, Chief Minister B S Yediyurappa said on Wednesday.

In an interview to, he also said the state intended to relax liquor sales, stopped since the 21-day lockdown was imposed to contain the spread of COVID-19, after April 14 in a bid to increase state revenues.

The chief minister said the state's legislators would take a 30 per cent salary cut.

According to officials, there were no COVID-19 cases in 12 districts of the total 30 districts in the state.

As on Wednesday, there were 181 COVID-19 cases in the state, including 5 deaths and 28 discharges.

"If the Prime Minister suggests to states to take decision (on lock-down) based on the situation in their respective states, my position is to take a call (on roll-back) in districts free from COVID-19", Yediyurappa said.

This is to allow people to go about their business and move about within the district and not from one district to another, after April 14, after taking the approval of the Prime Minister, he said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.